Literature DB >> 21469392

A stronger role for science.

.   

Abstract

Drug development is inherently risky, but if perceived short-term business imperatives outweigh sound science in decision-making, the magnitude of these risks might become unsustainable.

Mesh:

Substances:

Year:  2011        PMID: 21469392     DOI: 10.1038/nrd3387

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  4 in total

Review 1.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

2.  When are "positive" clinical trials in oncology truly positive?

Authors:  Alberto Ocana; Ian F Tannock
Journal:  J Natl Cancer Inst       Date:  2010-12-03       Impact factor: 13.506

3.  Industry, clinical trials, and the cost of cancer drugs: an investor's perspective.

Authors:  Tony Fiorino
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

4.  Trial watch: phase III and submission failures: 2007-2010.

Authors:  John Arrowsmith
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

  4 in total
  2 in total

1.  Medicinal chemistry for 2020.

Authors:  Seetharama D Satyanarayanajois; Ronald A Hill
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

Review 2.  The future of the pharmaceutical sciences and graduate education: recommendations from the AACP Graduate Education Special Interest Group.

Authors:  Susanna Wu-Pong; Jogarao Gobburu; Stephen O'Barr; Kumar Shah; Jason Huber; Daniel Weiner
Journal:  Am J Pharm Educ       Date:  2013-05-13       Impact factor: 2.047

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.